Navigation Links
MSU researchers testing vaccine to help people quit smoking

EAST LANSING, Mich. In a unique twist to a decades-old health crisis, Michigan State University researchers are testing a new vaccine to help people quit smoking and avoid relapses.

Using a vaccine as opposed to patches or gums, which attempt to wean people off nicotine is a novel approach to the addiction that results in more than $192 billion in health care costs each year, according to federal estimates.

The vaccine, called NicVAX, is being developed and manufactured by Nabi Biopharmaceuticals of Rockville, Md. It will be tested at 25 sites nationwide.

Jonathan Henry, an associate professor with MSU's Department of Psychiatry and the Clinical and Translational Sciences Institute, is leading the clinical trial at MSU.

"Using a vaccine to treat nicotine dependence is one of the most unique approaches to battling addiction," Henry said. "We are very hopeful this strategy will help smokers kick the habit."

The vaccine works by preventing a smoker from "feeling good" while smoking. When nicotine enters the bloodstream, it quickly crosses the blood-brain barrier, triggering the release of stimulants such as dopamine that provide the smoker with a positive sensation, eventually leading to addiction.

NicVAX stimulates the immune system to produce antibodies that bind with and prevent nicotine from crossing the blood-brain barrier, essentially preventing the highly-addictive pleasure sensation experienced by smokers.

Vaccine developers hope that prevention helps people quit smoking, and because the antibodies remain in the bloodstream for several months, the vaccine could be effective in preventing relapse. With current smoking-cessation therapies, relapse rates can be as high as 90 percent in the first year after a smoker quits.

During the clinical trial, participants will receive the vaccine several times throughout a 12-month period. Results from the placebo-controlled study are expected to be available in early 2012. If the clinical trial proves successful, Nabi Biopharmaceuticals will Food and Drug Administration approval shortly thereafter.

At MSU, about 50 people will take part in the clinical trial, which nationwide will test 1,000 participants. Henry and his team of researchers, from the departments of Psychiatry and Family Medicine and the Clinical and Translational Sciences Institute, are seeking subjects for the trial.

Participants must be smokers ages 18 to 65 who smoke at least 10 cigarettes per day and are motivated to quit.


Contact: Jason Cody
Michigan State University

Related biology news :

1. OU WaTER Center researchers providing solutions in developing countries
2. Researchers embark on work to control the prion epidemic affecting deer in the USA
3. Are invasives bad? Not always, say Brown researchers
4. UGA researchers use patented SERS technique to rapidly, accurately detect rotavirus strain
5. 700 international researchers gather for Great Lakes Research Conference
6. Biofuel chemistry more complex than petroleum, say Sandia and Lawrence Livermore researchers
7. Researchers share insights into RNA
8. UT Southwestern researchers find mechanism that may stop E. coli from developing in cattle
9. A new effective strategy for treating tobacco addiction was developed by researchers from the CAS
10. Researchers offer first proof that chemicals from seaweeds damage coral on contact
11. UNC researchers receive $100,000 Grand Challenges Exploration Grant to develop male contraceptive
Post Your Comments:
(Date:11/20/2015)... NXTD ) ("NXT-ID" or the ... mobile commerce market and creator of the Wocket® smart ... recently interviewed on The RedChip Money Report ... on Bloomberg Europe , Bloomberg Asia, Bloomberg Australia, ... NXTD ) ("NXT-ID" or the "Company"), a biometric authentication ...
(Date:11/18/2015)... -- As new scientific discoveries deepen our understanding of how ... face challenges in better using that knowledge to guide ... more children continue to survive pediatric cancer, that counseling ... John M. Maris, M.D ., a pediatric ... . --> John M. Maris, M.D ...
(Date:11/17/2015)... 2015 Paris , ... --> Paris , qui s,est tenu ... le leader de l,innovation biométrique, a inventé le premier ... empreintes sur la même surface de balayage. Jusqu,ici, deux ... pour les empreintes digitales. Désormais, un seul scanner est ...
Breaking Biology News(10 mins):
(Date:11/24/2015)... Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be ... York on Wednesday, December 2 at 9:30 a.m. ET/6:30 ... CEO, will provide a corporate overview. th Annual ... 1:00 p.m. ET/10:00 a.m. PT . Jim Mazzola , ... corporate overview. --> th Annual Oppenheimer Healthcare Conference ...
(Date:11/24/2015)... QUEBEC CITY , Nov. 24, 2015 /PRNewswire/ - ... the request of IIROC on behalf of the Toronto ... this news release there are no corporate developments that ... price. --> --> ... --> . --> Aeterna Zentaris ...
(Date:11/24/2015)... ... 2015 , ... The Academy of Model Aeronautics (AMA), led by its Executive ... Multirotor Grand Prix, to represent the First–Person View (FPV) racing community. , FPV racing ... this type of racing and several new model aviation pilots have joined the community ...
(Date:11/24/2015)... CITY , Nov. 24, 2015 /PRNewswire/ - ... "Company") announced today that the remaining 11,000 post-share ... Share Purchase Warrants (the "Series B Warrants") subject ... were exercised on November 23, 2015, which will ... Shares.  After giving effect to the issuance of ...
Breaking Biology Technology: